VEGF and VEGFR family members are expressed by neoplastic cells of NF1-associated tumors and may play an oncogenic role in malignant peripheral nerve sheath tumor growth through an autocrine loop.


Journal

Annals of diagnostic pathology
ISSN: 1532-8198
Titre abrégé: Ann Diagn Pathol
Pays: United States
ID NLM: 9800503

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 14 06 2022
accepted: 17 06 2022
pubmed: 2 7 2022
medline: 19 10 2022
entrez: 1 7 2022
Statut: ppublish

Résumé

Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder. The role of angiogenesis and VEGF pathway in the pathogenesis of neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs) remains poorly understood. We assessed the expression of VEGF and VEGFR family members in cohorts of plexiform neurofibromas (pNF), MPNSTs and MPNST cell lines at transcript [pNF, n = 49; MPNST, n = 34] and protein levels [pNF, n = 21; MPNST, n = 9]. VEGF and VEGFR members were variably expressed in cell lines. VEGFA (p = 3.10

Identifiants

pubmed: 35777330
pii: S1092-9134(22)00099-5
doi: 10.1016/j.anndiagpath.2022.151997
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins c-akt EC 2.7.11.1
Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151997

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflict of interest to declare. This work was supported by Roche laboratory (Bourse de recherche mélanome et autres tumeurs cutanées (hors lymphomes)) [2013].

Auteurs

Benjamin Bonsang (B)

AP-HP, Groupe hospitalier Henri Mondor, Department of Pathology, 51 avenue du Maréchal Lattre de Tassigny, F-94010 Créteil, France.

Laurent Maksimovic (L)

AP-HP, Groupe hospitalier Henri Mondor, Department of Pathology, 51 avenue du Maréchal Lattre de Tassigny, F-94010 Créteil, France.

Pascale Maille (P)

AP-HP, Groupe hospitalier Henri Mondor, Department of Pathology, 51 avenue du Maréchal Lattre de Tassigny, F-94010 Créteil, France.

Nadine Martin (N)

Paris Est Créteil University, Faculté de Médecine, F-94010 Créteil, France; INSERM, Institut Mondor de recherche Biomédicale (IMRB) U955, NeuroFibroma and Lymphoma oncogenesis (NFL) team, Henri Mondor Hospital, 51 avenue du Maréchal Lattre de Tassigny, F-94010 Créteil, France.

Ingrid Laurendeau (I)

Institut Cochin, Inserm U1016, CNRS UMR8104, Université de Paris, CARPEM, F-75014 Paris, France.

Eric Pasmant (E)

Institut Cochin, Inserm U1016, CNRS UMR8104, Université de Paris, CARPEM, F-75014 Paris, France; AP-HP, Centre-Université de Paris, Department of Genetics, DMU BioPhyGen, Hôpital Cochin, 24 rue du faubourg Saint-Jacques, F-75014 Paris, France.

Ivan Bièche (I)

Institut Cochin, Inserm U1016, CNRS UMR8104, Université de Paris, CARPEM, F-75014 Paris, France; Department of Genetics, Institut Curie, F-75006 Paris, France.

Justin Deschamps (J)

AP-HP, Groupe hospitalier Henri Mondor, Department of Pathology, 51 avenue du Maréchal Lattre de Tassigny, F-94010 Créteil, France.

Pierre Wolkenstein (P)

Paris Est Créteil University, Faculté de Médecine, F-94010 Créteil, France; INSERM, Institut Mondor de recherche Biomédicale (IMRB) U955, NeuroFibroma and Lymphoma oncogenesis (NFL) team, Henri Mondor Hospital, 51 avenue du Maréchal Lattre de Tassigny, F-94010 Créteil, France; AP-HP, Groupe hospitalier Henri Mondor-Albert Chenevier, Department of Dermatology and National Neurofibromatosis Centre, 51 avenue du Maréchal Lattre de Tassigny, F-94010 Créteil, France.

Nicolas Ortonne (N)

AP-HP, Groupe hospitalier Henri Mondor, Department of Pathology, 51 avenue du Maréchal Lattre de Tassigny, F-94010 Créteil, France; Paris Est Créteil University, Faculté de Médecine, F-94010 Créteil, France; INSERM, Institut Mondor de recherche Biomédicale (IMRB) U955, NeuroFibroma and Lymphoma oncogenesis (NFL) team, Henri Mondor Hospital, 51 avenue du Maréchal Lattre de Tassigny, F-94010 Créteil, France. Electronic address: nicolas.ortonne@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH